St. Jude’s Team Empowering Global Research Community, continued from page 1 computing environment—which might take hours or even days,” Gout noted. “It was a big mess.” The solution – St. Jude Cloud: a platform in the cloud, developed at St. Jude Alex Gout to share all of the rich genomic pediatric cancer data generated over the previous ten years. From its launch in the spring of 2018 through August 2019, more than 50,000 users from across the world had accessed the Cloud. Today, less than 6 months later, that figure has more than doubled, and now exceeds 100,000 users, including 61 institutions in 16 countries. St. Jude Cloud, a partnership with Microsoft and DNAnexus, offers three interactive data-sharing platforms where scientists can use an array of exceptional tools to manipulate data in the form of whole genomes, whole exomes, and RNAsequenced data derived from pediatric cancer patients—rare data now available to doctors and researchers anywhere in the world. “The driving force behind any scientific endeavor is discovery and advancement of knowledge,” Gout reminds us. “Anyone in the pediatric cancer space is trying to discover or make advances toward better understanding of the disease and developing treatment. Therefore we want as many people looking at this data as possible, because the more brains we have on the case, the quicker we’re going to come up with discoveries and solutions to treating childhood cancers.” The more that’s shared, the more that’s learned; increased genome sequencing and analysis are revealing more and more about the long-term negative health effects of cancer treatment. Over time, lesstoxic interventions are replacing treatments like radiation, which is being eliminated as less toxic treatments are developed. Gout’s fascination with pediatric cancer genomics was home-grown in Australia, where he studied genetics as an undergraduate, followed by a graduate degree in computer science, a PhD in medical biology/infectious disease, and additional post-doctorate studies in pediatric
Is the missing
oncology genomics before spending time at the Broad Institute at Harvard-MIT in Boston as part of his post-doctoral focus. He returned to the U.S. in 2017 as editor for Nature Communications’ Cancer Genomics, a prestigious scientific journal— until Jinghui Zhang, PhD and chair of the St. Jude Dept. of Computational Biology, invited him to join the fledgling St. Jude Cloud project, late in 2018, as the project’s Scientific Lead. “It’s been a fantastic experience; St. Jude is an absolutely amazing place,” he adds. “The St. Jude Cloud project is really paving the way for how we share genomic data with the world, and how we analyze genomic data, as well. I’m so happy that I came!” His efforts shepherded the project into its next phase in May 2019—making real-time clinical genomics available in the Cloud. Instead of waiting for the publication of related research (the traditional path, which can sometimes take years) before sharing the data, St. Jude now uploads unmined, de-identified patient data on a monthly basis. “We don’t want to delay other people’s access to this data—and potentially finding their own discoveries,” says Gout. “Instead, as soon as we sequence the data and generate it, we want to put it out into the world. Because pediatric cancer is such a rare disease, we need a lot of data to find associations and commonalities and correlations in order to make discoveries. The faster we share, the faster we allow this discovery process to happen.” The Survivorship Portal, a new feature of St. Jude Cloud, was introduced last fall, as part of a National Cancer Institute (NCI)-funded project. “This is a fascinating study,” Gout marvels. “They’ve accumulated between 3,000 and 5,000 patients who have, once upon a time, been treated at St. Jude for cancer. Many of these survivors return to St. Jude voluntarily every year, to have more than 100 different phenotypes measured: their blood pressure, heart characteristics, eye strength, mental agility, weight, height, BMI, etc. We study their DNA, if they agree; we look at these clinical phenotypes, the cancer they had in the past, the treatment used, and consider whether or not those things have affected their lives moving forward, in
Let us help you keep your information safe! 6
Keep your ﬁnger on the pulse of Memphis’ healthcare industry. to begin receiving Memphis Medical News in print or on your tablet or smartphone
Former systems admin for UTHSC Over 17 years experience US Navy Network Security Microsoft Certified Networking services Security Specialist
programs to analyze the data in multiple locations at the same time.” Other potential participants in the collaborative cloud project include Kids First, at the Children’s Hospital of Philadelphia; and NCI’s Target Study, housed inside NCI Data Commons. “Collaborating with these other repositories and performing federated data analysis would allow us to leverage all of the data that each collectively has,” he notes. This would allow researchers to view scattered and rare cases, comparing commonalities—or lack thereof—without knocking on multiple virtual doors in order to gather and analyze valuable research data. “The federated data analysis project is something very cool that we’ll embark on very soon,” Gout believes.
PUBLISHER Pamela Z. Haskins firstname.lastname@example.org EDITOR R.B. Phillips email@example.com PHOTOGRAPHER Greg Campbell ADVERTISING INFORMATION 501.247.9189 Pamela Z. Haskins CREATIVE DIRECTOR Susan Graham firstname.lastname@example.org GRAPHIC DESIGNERS Susan Graham, Katy Barrett-Alley
• • • • • •
5, 10, or 15 years. “Proper analysis of these data sets may enable us to serve preventative measures when we’re treating another child with cancer,” he suggests, “by comparing the results shown for patients with a similar genomic profile, who received different therapies, as recorded in the Survivorship Portal. “The Survivorship Project is a really beautiful retrospective study whereby we can leverage the accumulated knowledge that we can get from previously treated patients, and how we develop that treatment strategy for future patients.” The newest evolution -- Today, St. Jude Cloud anticipates its newest evolution: Federated data analysis of collaborating but currently incompatible genomic clouds. “Those who hold major pediatric databases use different clouds, and don’t allow simultaneous access between them,” says Gout. “We have over 10,000 whole genomes sequenced within St. Jude Cloud,” he reminds us. “With such a large number of samples, we need to think about new ways to house and analyze this data—new ways to develop processing and analysis software protocols that allow us to work with other large data repositories. “This is a big paradigm shift in doing genomics research in computational biology and other medical research,” he points out. “St. Jude Cloud is the largest genetic sequencing repository in the world, but there are other very large sequencing repositories being born around the world as well. Rather than finding one place where we could combine all of this data, we’re striving towards a federated data analysis approach, whereby we leave all the data in these other large pediatric cancer repositories and develop software analysis
CONTRIBUTING WRITERS Lawrence Buser Judy Otto Cindy Sanders
All editorial submissions and press releases should be sent to editor@ memphismedicalnews.com
Subscription requests can be mailed to the address below or emailed to email@example.com. Memphis Medical News is now privately and locally owned by Ziggy Productions, LLC. P O Box 1842 Memphis, TN 38101- 1842 President: Pamela Z. Haskins Vice President: Patrick Rains Reproduction in whole or in part without written permission is prohibited. Memphis Medical News will assume no responsibility for unsolicited materials. All letters sent to Memphis Medical News will be considered the newspaper’s property and unconditionally assigned to Memphis Medical News for publication and copyright purposes.
John Pantall, Microsoft Certified 901.466.6358
your primary source for professional healthcare news